Boston Scientific Corporation (BSX)

Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is a low bar with consensus already tracking toward the bottom of guidance, but the real question is whether management can hold the line on full-year guidance — any incremental WATCHMAN or EP deterioration beyond what was telegraphed at the Bernstein Conference would be the key downside risk.

Boston Scientific heads into Q2 2026 with the most challenging quarterly setup in recent memory: management explicitly flagged Q2 as the “toughest quarter of the year” on the Q1 call, citing difficult dollar sequential comps in both EP and WATCHMAN, and then reiterated at the May 27 Bernstein Conference that WATCHMAN US dollar revenue would be flat sequentially in both Q2 and Q3. Consensus has drifted toward the low end of the 5–7% organic growth guidance range (current consensus at ~5.5% organic growth), and the bar for adjusted EPS of ~$0.83 sits just above the $0.82–$0.84 guidance midpoint — a manageable hurdle if execution holds. The stock has already absorbed a brutal de-rating, falling ~29% since the Q1 print (vs. IHI down ~1% and SPY up ~4%), so much of the bad news is priced in; however, the July 27 announcement of a major restructuring plan ($700–$800M in charges, $500M in annual savings) adds a new variable that could either be read as a confidence signal on long-term margin delivery or as an admission that the cost structure needs a harder reset than previously communicated. The single biggest wildcard is whether the standalone WATCHMAN procedure trajectory has stabilized or continued to deteriorate through June — any sequential improvement in WATCHMAN volumes would be a meaningful positive surprise given how low expectations have been set, while further deterioration would put the full-year mid-teens WATCHMAN growth guide at risk and likely pressure the stock further.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low bar heading into Q2 — estimates have drifted toward the bottom of guidance on both revenue and EPS. WATCHMAN revenue is the bigger swing factor: flat sequential dollar growth is baked in, but any deviation (positive or negative) will drive the stock reaction more than the headline organic growth number.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha consensus and actuals data; BSX Q1 2026 Earnings Call transcript (April 22, 2026); Bernstein Strategic Decisions Conference transcript (May 27, 2026).

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Adjusted EPS (Diluted — Operating)

BSX has beaten adjusted EPS consensus in each of the last 8 quarters, though the magnitude of beats has compressed materially — from double-digit surprises in 2024–2025 to low single-digit beats in the most recent two quarters, reflecting a tighter guidance range and more conservative street modeling post the Q1 2026 guide-down.

KPI 2: Total Revenue

BSX has beaten revenue consensus in each of the last 8 quarters, but the beat magnitude has compressed sharply — from 2–4% beats in 2024 to near in-line prints in the last two quarters. With Q2 2026 consensus already at the low end of guidance, the bar is set for a clean in-line print rather than a meaningful beat.

Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has not been formally revised since the Q1 2026 earnings call, but management’s tone at the May 27 Bernstein Conference was incrementally cautious — explicitly flagging flat sequential WATCHMAN dollar revenue in both Q2 and Q3, which pushed consensus toward the low end of the range. The restructuring plan announced July 27 is a new variable not previously in guidance.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have moved lower since the Q1 print — Q2 2026 consensus revenue was revised down ~$30M and EPS down ~$0.004 from the post-Q1 baseline, tracking toward the low end of guidance. Full-year estimates have also drifted below the guidance midpoint, suggesting the street is not giving management the benefit of the doubt on a second-half recovery.

The most notable revision is WATCHMAN: consensus was cut ~$31M (5.7%) from the post-Q1 baseline after management’s Bernstein commentary explicitly guided to flat sequential US dollar revenue. Even at current consensus of $514M, there may be modest downside risk if standalone procedure volumes have not stabilized. Full-year estimates tracking ~1% below the guidance midpoint on both revenue and EPS suggests the street is positioned for the low end of the range.

Source: Visible Alpha consensus and actuals data.

5. Stock Performance

Key Takeaway: BSX has massively underperformed since Q1 earnings — down ~29% vs. IHI down ~1% and SPY up ~4% — driven almost entirely by multiple compression and sentiment deterioration following the guidance cut and Bernstein Conference commentary. The stock is now trading near multi-year lows, suggesting much of the bad news is priced in, but a re-rating requires evidence of stabilization in WATCHMAN and EP.

BSX vs. IHI (MedTech ETF) vs. S&P 500 — Indexed to 100 at April 22, 2026 (Last Earnings Date). Source: Yahoo Finance.

Key observations:

• BSX fell sharply on the Q1 2026 print (April 22) despite a slight EPS beat, as the full-year guidance cut from 10–11% to 6.5–8% organic growth dominated the reaction. The stock had already declined ~37% YTD entering the print, so the initial reaction was muted.
• The ASR announcement and MiRus investment (May 18) provided a brief ~10% relief rally, as the $2B buyback signaled management confidence in the stock at depressed levels.
• The Bernstein Strategic Decisions Conference (May 27) was the most damaging event post-Q1 — BSX fell roughly double digits on the day as management reiterated (rather than improved) guidance and explicitly flagged flat sequential WATCHMAN dollar revenue in Q2 and Q3, pushing the stock to multi-year lows.
• The restructuring plan announcement (July 27) — $700–$800M in charges, $500M in annual savings — provided a modest lift, with the stock recovering from ~$43 to ~$46 in the days surrounding the announcement.
• IHI (MedTech ETF) has been essentially flat since the Q1 print, confirming that BSX’s underperformance is company-specific rather than sector-driven. SPY has gained ~4% over the same period.

6. Peer Commentaries — Read-Through Analysis (Last 60 Days, Q2 2026 Relevant)

Key Takeaway: Peer commentary from Abbott (Q2 2026), Medtronic (Q4 FY2026, reported May 20), and Edwards Lifesciences (Q2 2026) provides a mixed but net-cautious read-through for BSX: EP market growth is robust and accelerating (positive for FARAPULSE), but competitive intensity in PFA is intensifying with Abbott’s Bolt 2.0 moving to full market release in Q3 and Medtronic’s Sphere-9 gaining 8 points of US share in a single quarter. WATCHMAN-specific read-throughs are limited but Abbott’s commentary on the LAA market (concomitant growth, interventional cardiology opportunity) is directionally consistent with BSX’s own narrative.

Abbott Laboratories (ABT) — Q2 2026 Earnings (July 16, 2026)

Relevance: ABT is BSX’s most direct competitor in both PFA (Bolt/Volt catheter) and LAA closure (Amulet 360). ABT’s Q2 2026 results and commentary are the most current and most directly relevant read-through for BSX’s Q2 2026 print.

• EP market growing at low-teens, accelerating in H2 2026. ABT reported low-teens EP growth in Q2 2026, with Europe up 20%. Management guided for EP growth to “accelerate in the second half for sure and outperform the market.” This is a positive read-through for overall EP market growth, which benefits BSX’s FARAPULSE franchise. However, ABT is gaining share, which is a direct headwind for BSX.
• Bolt 2.0 PFA catheter launched in US in May; full market release in Q3 2026. ABT launched its next-generation Bolt PFA catheter in the US in May 2026 and expects to transition to full market release in Q3. This is a direct competitive escalation against FARAPULSE in the US market. ABT highlighted Bolt 2.0’s mapping integration and ASC suitability (sedation vs. general anesthesia) as key differentiators — both areas where BSX has been investing. This is a negative read-through for BSX’s US EP share trajectory in Q3 and beyond.
• ABT’s LAA strategy: Amulet 360 FDA submission complete, potential approval by year-end 2026. ABT completed its FDA submission for Amulet 360 and management expressed confidence in a potential year-end 2026 approval. ABT characterized the LAA market as a “$2 billion market” with a competitor holding 90% share (BSX/WATCHMAN), and explicitly stated its focus is on “market share capture.” Concomitant procedures are described as the primary growth driver, consistent with BSX’s own narrative. This is a negative medium-term read-through for WATCHMAN’s market share, though near-term impact is limited until Amulet 360 is approved and launched.
• Medtech procedure volumes: Medicare-driven, inelastic demand. ABT management pushed back strongly on concerns about Medicaid disenrollment impacting medtech volumes, noting that Medicare (not Medicaid) is “by far the largest US payer” for devices, covering over two-thirds of ABT’s US cardio business. Demand for high-acuity, life-saving products is “very inelastic.” This is a positive read-through for BSX’s procedure volume assumptions and pushes back on macro headwind concerns.
• ABT raised full-year EPS guidance to $5.45–$5.60 and reaffirmed 6.5–7.5% comparable sales growth. ABT’s strong Q2 beat and raised guidance signals a healthy medtech environment broadly, which is a positive backdrop for BSX’s print.

Medtronic (MDT) — Q4 FY2026 Earnings (May 20, 2026)

Relevance: MDT is BSX’s most aggressive EP competitor, with its Affera/Sphere-9 PFA platform gaining significant US share. MDT’s Q4 FY2026 results (calendar Q1/Q2 2026) and FY2027 guidance are directly relevant to BSX’s EP competitive dynamics in Q2 2026.

• MDT CAS (Cardiac Ablation Solutions) grew 78% globally, 124% in the US, gaining 8 points of US share in a single quarter. This is the most direct and most negative read-through for BSX’s US EP business. MDT is now annualizing over $2B in CAS revenue and is “marching towards market leadership.” MDT holds ~15% US share and is growing at 2x+ the market rate. This directly corroborates BSX’s own acknowledgment of greater-than-expected US EP share loss.
• MDT’s Sphere-9 PFA saw 145% global growth; US installed base up 40% sequentially. MDT is rapidly expanding its PFA footprint in the US, with the Affera platform’s installed base growing 40% sequentially. MDT is also rolling out Prism-2 mapping software and launching Sphere-360 in Europe (US pivotal trial enrolling). This pipeline cadence suggests MDT’s competitive pressure on BSX will intensify through 2026 and into 2027.
• MDT guided FY2027 CAS impact to be “very similar to this year” with market growing mid-to-high teens and MDT growing “north of 2x the market rate.” This implies MDT expects to continue taking share from BSX (and others) through BSX’s Q3 and Q4 2026 reporting periods. This is a negative forward read-through for BSX’s US EP share trajectory.
• MDT Structural Heart was flat in the quarter, with US softer due to low-risk TAVR data; weekly US procedure volumes stabilized over last 8 weeks. This is a limited but neutral-to-positive read-through for BSX’s structural heart and ICVT businesses — procedure volumes are not collapsing.
• MDT guided FY2027 organic growth of 6.75–7.25% (underlying 5.5–6% ex-extra week). MDT’s guidance is broadly consistent with a mid-single-digit medtech growth environment, which is consistent with BSX’s own 6.5–8% organic growth guidance for FY2026.

Edwards Lifesciences (EW) — Q2 2026 Earnings (July 23, 2026)

Relevance: EW is a read-through for structural heart procedure volumes, TAVR market dynamics, and the LAA closure market (EW received US approval for Eclipsis, a surgical LAA technology). EW’s Q2 2026 results are the most recent peer print before BSX’s Q2 report.

• EW delivered stronger-than-expected Q2 2026 sales growth of 12.5%, raising full-year guidance to 10–11%. EW’s strong beat and raise is a positive read-through for the overall medtech procedure environment and structural heart volumes. EW raised TAVR guidance to 8–9% growth and TMT (mitral/tricuspid) guidance to $760–$780M.
• Global TAVR sales of $1.3B, up 10.5% YoY; US competitive position increased modestly. TAVR procedure volumes are healthy globally, with EW noting “sustained clinical momentum” and “proactive disease management of severe AS.” This is a positive read-through for BSX’s ICVT and structural heart businesses, which benefit from a healthy cath lab environment.
• EW received US approval for Eclipsis (surgical LAA closure technology) and plans a major rollout in H2 2026. Eclipsis is a surgical (concomitant) LAA closure device, which competes in the concomitant WATCHMAN segment. This is a modest negative read-through for BSX’s concomitant WATCHMAN growth, though the surgical segment is distinct from the catheter-based WATCHMAN FLX market.
• EW expects normalized Q3 2026 seasonality; Q3 2026 guidance of $1.63–$1.71B in sales. EW’s Q3 guidance implies continued healthy procedure volumes, which is a positive read-through for BSX’s Q3 2026 setup (though BSX’s Q3 is already guided to be challenging due to WATCHMAN sequential dollar comps).
• CMS TAVR NCD update expected in September 2026; potential asymptomatic indication coverage. The TAVR NCD update is a positive for the structural heart market broadly and could benefit BSX’s ICVT business. More importantly, it signals that CMS is actively updating coverage policies for structural heart devices — a positive precedent for BSX’s pending WATCHMAN label expansion and NCD update application.

Peer Read-Through Summary Table

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the July 27 restructuring plan announcement — $700–$800M in charges and $500M in annual savings — which signals a more aggressive cost reset than previously communicated and could be a positive catalyst if management uses Q2 earnings to frame it as a margin expansion accelerator. The $2B ASR completion and MiRus TAVR investment are also significant.

• July 27, 2026 — BSX announces 2026 Restructuring Plan: $700–$800M in pre-tax charges, $500M in annual savings. The Board approved a global restructuring program targeting supply chain optimization, functional transformation, and organizational structure evolution. Charges include $300–$350M in transfer costs, $275–$300M in termination benefits, and $125–$150M in other costs. Approximately $600–$700M will be cash outlays. Activities to be initiated in 2026 and substantially completed by end of 2029. Management noted a “substantial portion” of the $500M savings will be reinvested in strategic growth initiatives. Implication: This is a significant structural action that goes beyond prior efficiency messaging. If management frames this as enabling the LRP margin targets (150 bps expansion) despite the revenue guide-down, it could be a positive catalyst. However, the scale of charges and the 3-year timeline suggest the cost structure issues are more entrenched than previously acknowledged.
• May 18, 2026 — BSX executes $2B Accelerated Share Repurchase (ASR) with JPMorgan Chase; final settlement by June 30, 2026. BSX entered into a $2B ASR agreement, with final settlement completed by June 30, 2026. Approximately $3B remains under the $5B authorization. Implication: The ASR is a strong signal of management confidence in the stock at depressed levels (~$55 at time of announcement). The completion of the ASR by June 30 means the full EPS benefit will be reflected in Q2 2026 results, providing a modest tailwind to adjusted EPS.
• May 18, 2026 — BSX invests ~$1.5B for ~34% equity stake in MiRus LLC; exclusive option to acquire SIEGEL balloon-expandable TAVR system. BSX made a strategic investment in MiRus LLC, securing an exclusive option to acquire the SIEGEL TAVR system (built on a proprietary rhenium alloy, currently in the STAR pivotal trial) for additional milestone-contingent payments. The option also includes mitral and tricuspid assets. Management characterized MiRus as potentially disruptive to the TAVR market in a manner analogous to FARAPULSE in EP. Implication: This is a long-dated option on a potentially differentiated TAVR platform, but near-term financial impact is limited. The $1.5B investment is significant capital deployment and will be watched for dilution impact.
• May 27, 2026 — Bernstein Strategic Decisions Conference: management reiterates guidance, explicitly flags flat sequential WATCHMAN US dollar revenue in Q2 and Q3. BSX stock fell roughly double digits on the day as management reiterated (rather than improved) guidance and provided the most explicit WATCHMAN trajectory commentary to date. Management confirmed 91% WATCHMAN market share, standalone procedure deceleration, and the expectation of flat sequential US dollar revenue in both Q2 and Q3. Implication: This was the most damaging post-Q1 event for the stock. The explicit Q3 WATCHMAN guidance (flat sequential) was new and negative, extending the headwind timeline. Consensus has since been revised down to reflect this.
• May 5, 2026 — BSX shareholders approve governance changes; Penumbra acquisition proceeding toward H2 2026 close. The shareholder vote passed, clearing a key milestone for the Penumbra acquisition. Remaining regulatory clearances are pending. Implication: Penumbra close in H2 2026 will add revenue but also dilution; management has reaffirmed LRP targets are unchanged including Penumbra.
• July 23, 2026 — Edwards Lifesciences Q2 2026 beat and raise; TAVR up 10.5%, TMT up 44.8%. EW’s strong Q2 results signal a healthy structural heart and cath lab environment heading into BSX’s print. Implication: Positive read-through for BSX’s ICVT and cardiovascular businesses.
• July 16, 2026 — Abbott Q2 2026 beat; EP low-teens growth, Bolt 2.0 launched in US, Amulet 360 FDA submission complete. ABT’s EP acceleration and competitive product launches are a direct headwind for BSX’s US EP share. Implication: Negative read-through for BSX US EP share in Q2 and Q3 2026.
• May 20, 2026 — Medtronic Q4 FY2026: CAS grew 78% globally, 124% in US, gaining 8 points of US share. MDT’s Sphere-9 PFA platform is aggressively taking US EP share. Implication: Directly corroborates BSX’s acknowledged US EP share loss; negative for BSX US EP trajectory.
• March 28, 2026 (ACC.26) — CHAMPION AF trial met all primary and secondary endpoints; HI-PEITHO met primary endpoint. Both published in NEJM. CHAMPION supports WATCHMAN label expansion (FDA submission made; 9–12 month approval timeline). HI-PEITHO supports EKOS as first-line therapy for intermediate-risk PE. Implication: Long-term positive catalysts for WATCHMAN TAM expansion and EKOS market development, but near-term commercial impact is limited pending guideline updates and reimbursement changes.

8. Insider Transaction Activity

Key Takeaway: The most notable signal is a cluster of open-market purchases by three independent directors in May 2026 at prices in the $47–$57 range — a meaningful vote of confidence at depressed levels. The CEO’s gift of 386,755 shares to a trust is not a market signal. No open-market sales by executives were recorded in the period.

The cluster of three independent director open-market purchases in May 2026 (Habiger, Ludwig, Pegus) at prices in the $47–$57 range is the most notable insider signal in the period. These are discretionary purchases made after the Q1 guide-down and Bernstein Conference, suggesting board-level conviction that the stock is undervalued at current levels. No open-market sales by executives or directors were recorded. The CEO’s gift of 386,755 shares to a trust (Code G) is a routine estate/tax planning transaction and carries no market signal. All executive transactions were routine RSU vestings with mandatory tax withholding.

Source: SEC Form 4 filings, Insider Transaction Data.